The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study

Pharmacogenetics and Genomics

Volumn 24, Issue 1, 2014, Pages 43-51

  De Keyser, Catherine E ^a,b   Peters, Bas J M ^e,f   Becker, Matthijs L ^a,g   Visser, Loes E ^a,c   Uitterlinden, André G ^a,d   Klungel, Olaf H ^e   Verstuyft, Céline ^h   Hofman, Albert ^a,d   Maitland Van Der Zee, Anke Hilse ^e   Stricker, Bruno H ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Inspectorate for Health Care   (Netherlands)

^c Pharmacy Foundation of the Hague Hospitals HAGA   (Netherlands)

^d Netherlands Consortium for Healthy Ageing   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

^f ST ANTONIUS HOSPITAL   (Netherlands)

^g Hospital Pharmacy of Haarlem   (Netherlands)

^h BICÊTRE HOSPITAL   (France)

Author keywords

Adverse drug reaction; Atorvastatin; C.521T>C; Pharmacogenetics; Simvastatin; SLCO1B1

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1;

ADULT; AGED; ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HOSPITAL DISCHARGE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT; VERY ELDERLY;

AGED; AGING; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CYTOSINE; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC ASSOCIATION STUDIES; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PYRROLES; RISK FACTORS; SEX CHARACTERISTICS; SIMVASTATIN; THYMINE;

EID: 84891036315     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000018     Document Type: Article

References (41)

1. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389. (Pubitemid 24365311)
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
3. Tonkin A, Aylward P, Colquhoun D, Glasziou P, Harris P, Hunt D, et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-1357. (Pubitemid 28509344)
4. Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
5. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992; 33: 1569-1582.
6. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
7. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80: 565-581. (Pubitemid 44908269)
8. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-1690. (Pubitemid 37430274)
9. Mangravite LM, Krauss RM. Pharmacogenomics of statin response. Curr Opin Lipidol 2007; 18: 409-414. (Pubitemid 47051919)
10. Mangravite LM,Wilke RA, Zhang J, Krauss RM. Pharmacogenomics of statin response. Curr Opin Mol Ther 2008; 10: 555-561.
11. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009; 54: 1609-1616.
12. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011; 63: 157-181.
13. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15 + C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 2005; 15: 513-522. (Pubitemid 41017600)
14. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007; 8: 787-802. (Pubitemid 47288978)
15. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158: 693-705.
16. Peters BJ, Klungel OH, Visseren FL, de Boer A, Maitland-van der Zee AH. Pharmacogenomic insights into treatment and management of statininduced myopathy. Genome Med 2009; 1:120.
17. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006; 16: 873-879. (Pubitemid 44772805)
18. Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006; 372: 432-443.
19. SEARCH Collaborative Group. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 2008; 359: 789-799.
20. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 2010; 87: 130-133.
21. WHO Collaborating Centre for Drugs Statistics Methodology. Complete ATC index 2010. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health. Available at: http://www.whocc.no/atc-ddd-index. [Accessed 22 September 2012].
22. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991; 7: 403-422.
23. Hofman A, van Duijn CM, Franco OH, Ikram MA, Janssen HL, Klaver CC, et al. The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol 2011; 26: 657-686.
24. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol Drug Saf 2010; 19: 75-81.
25. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
26. Richards JB, Rivadeneira F, Inouye M, Pastinen TM, Soranzo N,Wilson SG, et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 2008; 371: 1505-1512.
27. International HapMap C. The International HapMap Project. Nature 2003; 426: 789-796.
28. Peters BJ, Pett H, Klungel OH, Stricker BH, Psaty BM, Glazer NL, et al. Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI. Atherosclerosis 2011; 217: 458-464.
29. Peters BJ, Rodin AS, Klungel OH, van Duijn CM, Stricker BH, van't Slot R, et al. Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. Pharmacogenomics 2010; 11: 1065-1076.
30. Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2011; 12: 233-237.
31. Donnelly LA, Doney AS, Tavendale R, Lang CC, Pearson ER, Colhoun HM, et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther 2011; 89: 210-216.
32. Santos PC, Gagliardi AC, Miname MH, Chacra AP, Santos RD, Krieger JE, et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol 2011; 68: 273-279.
33. Varma MV, Rotter CJ, Chupka J, Whalen KM, Duignan DB, Feng B, et al. pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm 2011; 8: 1303-1313.
34. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 2006; 80: 356-366. (Pubitemid 44465886)
35. Hubacek JA, Dlouha D, Adámkova V, Lanska V, Ceska R, Vrablik M. Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy. Neuro Endocrinol Lett 2012; 33 (Suppl 2): 22-25.
36. Cummins CL,Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 2002; 72: 474-489. (Pubitemid 36237718)
37. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004; 57: 6-14. (Pubitemid 38067945)
38. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 2007; 82: 87-96. (Pubitemid 46944201)
39. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009; 41: 67-76.
40. Warrington JS, Greenblatt DJ, von Moltke LL. The effect of age on P-glycoprotein expression and function in the Fischer-344 rat. J Pharmacol Exp Ther 2004; 309: 730-736. (Pubitemid 38542629)
41. Penning-van Beest FJ, Termorshuizen F, Goettsch WG, Klungel OH, Kastelein JJ, Herings RM. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007; 28: 154-159.